Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Mar-Apr;18(2):109-16.
doi: 10.1080/10550490902772785.

Early outcomes following low dose naltrexone enhancement of opioid detoxification

Paolo Mannelli  1 , Ashwin A Patkar, Kathleen Peindl, Edward Gottheil, Li-Tzy Wu, David A Gorelick
Affiliations
Randomized Controlled Trial

Early outcomes following low dose naltrexone enhancement of opioid detoxification

Paolo Mannelli et al. Am J Addict. 2009 Mar-Apr.

Abstract

Although withdrawal severity and treatment completion are the initial focus of opioid detoxification, post-detoxification outcome better defines effective interventions. Very low dose naltrexone (VLNTX) in addition to methadone taper was recently associated with attenuated withdrawal intensity during detoxification. We describe the results of a seven-day follow-up evaluation of 96 subjects who completed inpatient detoxification consisting of the addition of VLNTX (0.125 or 0.250 mg per day) or placebo to methadone taper in a double blind, randomized investigation. Individuals receiving VLNTX during detoxification reported reduced withdrawal and drug use during the first 24 hours after discharge. VLNTX addition was also associated with higher rates of negative drug tests for opioids and cannabis and increased engagement in outpatient treatment after one week. Further studies are needed to test the utility of this approach in easing the transition from detoxification to various follow-up treatment modalities designed to address opioid dependence.

Trial registration: ClinicalTrials.gov NCT00135759.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Subjective opioid withdrawal scores (SOWS) in 96 opioid-dependent subjects. On the day following detoxification (day seven), VLNTX-treated individuals reported significantly reduced withdrawal (ANCOVA, controlling for score on day six, F = 174.7 (2,94); p = 0.001). The shadowed area indicates inpatient detoxification.
FIGURE 2
FIGURE 2
Objective opioid withdrawal scores (OOWS) in 96 opioid-dependent subjects. On the day following detoxification (day seven), VLNTX-treated individuals showed significantly reduced withdrawal (ANCOVA, controlling for scores on day six, F = 169.5 (2,96); p = 0.001). The shadowed area indicates inpatient detoxification.
See this image and copyright information in PMC

References

    1. Mattick R, Hall W. Are detoxification programmes effective? Lancet. 1996;347:97–100. - PubMed
    1. O’Connor P. Methods of detoxification and their role in treating patients with opioid dependence. JAMA. 2005;294:961–963. - PubMed
    1. Bradley BP, Phillips G, Green L, Gossop M. Circumstances surrounding the initial lapse to opiate use following detoxification. Br J Psychiatry. 1989;154:354–359. - PubMed
    1. Unnithan S, Gossop M, Strang J. Factors associated with relapse among opiate addicts in an out-patient detoxification programme. Br J Psychiatry. 1992;161:654–657. - PubMed
    1. Lowinson JH, Marion I, Joseph H, Langrod J, Salsitz EA, Payte JT. Methadone maintenance. In: Lowinson JH, Ruiz P, Millman RB, Langrod JG, editors. Substance abuse: a comprehensive textbook. 4. Baltimore: Lippincott, Williams & Wilkins; 2005. pp. 616–640.

Publication types

Associated data